Table 1 Baseline characteristics of MM patients
From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Parameters | MM patients (N = 105) |
|---|---|
Age (years) | 59.8 ± 9.1 |
Gender (n/%) | |
Male | 65 (61.9) |
Female | 40 (38.1) |
Immunoglobulin subtype (n/%) | |
IgG | 59 (56.1) |
IgA | 24 (22.9) |
Bence-Jones protein | 19 (18.1) |
IgD | 2 (1.9) |
IgM | 1 (1.0) |
Hb (g/dL) | 10.0 ± 2.4 |
Calcium (mg/dL) | 10.0 ± 1.8 |
Scr (mg/dL) | 1.6 ± 0.5 |
ALB (mg/dL) | 3.9 ± 0.7 |
β2-MG (mg/L) | 4.8 (2.8–8.4) |
LDH (U/L) | 191.7 (169.0–228.3) |
Durie-Salmon stage (n/%) | |
I | 4 (3.8) |
II | 49 (46.7) |
III | 52 (49.5) |
ISS stage (n/%) | |
I | 24 (22.9) |
II | 36 (34.3) |
III | 45 (42.8) |
Bone lesion (n/%) | 75 (71.4) |
Cytogenetics abnormality (n/%) | |
t (14; 16) translocation | 15 (14.3) |
Del (17p) | 14 (13.3) |
t (4; 14) translocation | 10 (9.5) |